Medigene AG: Medigene presents approaches for improving selection of neoantigens for use in cancer immunotherapy
- Automated in vitro testing could reveal better neoantigens that activate more effective killer T cell responses - Two…
- Automated in vitro testing could reveal better neoantigens that activate more effective killer T cell responses - Two…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announced that researchers from Oslo University Hospital presented an up…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX), today announced details on the Company's first clinical trial with T-ce…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announced today that it has granted an exclusive, worldwide license for…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company, announced the treatment start o…